Zelenirstat

Zelenirstat is an orally acitve, small-molecule, dual N-myristoyltransferase (NMT) inhibitor, with IC50s of 5 nM (NMT1) and 8 nM (NMT2), respectively. Zelenirstat can induce cell apoptosis, has anti-cancer activity, inhibits early B cell receptor (BCR) signaling, and can be used to study malignant lymphoma[1][2].

Product Specifications

CAS Number

[1215011-08-7]

Product Name Alternative

PCLX-001

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

N-myristoyltransferase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pclx-001.html

Concentration

10mM

Purity

99.76

Solubility

DMSO : 8.93 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(NC1=C(C)N(C)N=C1CC(C)C)(C2=C(Cl)C=C(C3=CC(N4CCNCC4)=NC=C3)C=C2Cl)=O

Molecular Formula

C24H30Cl2N6O2S

Molecular Weight

537.51

Precautions

H302, H315, H319

References & Citations

[1]Michael Weickert, et al. Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies. Blood. 2019. 134 (s1) :3362.|[2]Beauchamp E, et al. Targeting N-myristoylation for therapy of B-cell lymphomas. Nat Commun. 2020 Oct 22;11 (1) :5348.